HK1210949A1 - Combinations and uses thereof - Google Patents

Combinations and uses thereof

Info

Publication number
HK1210949A1
HK1210949A1 HK15111752.8A HK15111752A HK1210949A1 HK 1210949 A1 HK1210949 A1 HK 1210949A1 HK 15111752 A HK15111752 A HK 15111752A HK 1210949 A1 HK1210949 A1 HK 1210949A1
Authority
HK
Hong Kong
Prior art keywords
combinations
Prior art date
Application number
HK15111752.8A
Other languages
English (en)
Chinese (zh)
Inventor
簡．恩德爾
利莎．羅杰克加爾
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HK1210949A1 publication Critical patent/HK1210949A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
HK15111752.8A 2012-09-25 2015-11-30 Combinations and uses thereof HK1210949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705172P 2012-09-25 2012-09-25
US201361774595P 2013-03-08 2013-03-08
PCT/EP2013/069858 WO2014048921A1 (en) 2012-09-25 2013-09-24 Combinations and uses thereof

Publications (1)

Publication Number Publication Date
HK1210949A1 true HK1210949A1 (en) 2016-05-13

Family

ID=49237209

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111752.8A HK1210949A1 (en) 2012-09-25 2015-11-30 Combinations and uses thereof

Country Status (23)

Country Link
US (1) US9579378B2 (xx)
EP (1) EP2900232B1 (xx)
JP (1) JP6426093B2 (xx)
KR (1) KR102171669B1 (xx)
CN (1) CN104684552B (xx)
AU (1) AU2013322806C1 (xx)
BR (1) BR112015006731A2 (xx)
CA (1) CA2885792C (xx)
DK (1) DK2900232T3 (xx)
ES (1) ES2658953T3 (xx)
HK (1) HK1210949A1 (xx)
HR (1) HRP20171964T1 (xx)
HU (1) HUE036518T2 (xx)
IL (1) IL237926B (xx)
LT (1) LT2900232T (xx)
MX (1) MX368288B (xx)
NZ (1) NZ706147A (xx)
PL (1) PL2900232T3 (xx)
PT (1) PT2900232T (xx)
RU (1) RU2650618C2 (xx)
SG (1) SG11201502163QA (xx)
WO (1) WO2014048921A1 (xx)
ZA (1) ZA201501980B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566915A (en) 2005-10-12 2011-09-30 Morphosys Ag Generation and profiling of human derived therapeutic antibodies specific for human CD38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CR20170086A (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-cd38
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
MX2018000265A (es) 2015-06-22 2018-05-23 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina.
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
KR20180067693A (ko) 2015-11-03 2018-06-20 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 제제 및 이의 용도
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2017226960B2 (en) * 2016-03-04 2024-03-21 Morphosys Ag Clinical assessment of M-protein response in multiple myeloma
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
DK2567976T3 (en) 2005-03-23 2017-10-23 Genmab As ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYLOMA
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
NZ566915A (en) 2005-10-12 2011-09-30 Morphosys Ag Generation and profiling of human derived therapeutic antibodies specific for human CD38
CA2664740C (en) 2006-09-26 2021-11-16 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
PL2992013T3 (pl) 2013-04-29 2020-09-07 Teva Pharmaceuticals Australia Pty Ltd Przeciwciała anty-cd38 i fuzje z atenuowanym interferonem alfa-2b

Also Published As

Publication number Publication date
AU2013322806B2 (en) 2017-11-30
CN104684552A (zh) 2015-06-03
CN104684552B (zh) 2018-08-07
PL2900232T3 (pl) 2018-05-30
EP2900232A1 (en) 2015-08-05
CA2885792A1 (en) 2014-04-03
ES2658953T3 (es) 2018-03-13
RU2650618C2 (ru) 2018-04-16
US20150238603A1 (en) 2015-08-27
MX368288B (es) 2019-09-27
MX2015003589A (es) 2015-08-12
HUE036518T2 (hu) 2018-07-30
JP6426093B2 (ja) 2018-11-28
EP2900232B1 (en) 2017-11-15
WO2014048921A1 (en) 2014-04-03
LT2900232T (lt) 2018-02-26
NZ706147A (en) 2018-10-26
BR112015006731A2 (pt) 2017-07-04
KR20150090030A (ko) 2015-08-05
PT2900232T (pt) 2018-02-09
IL237926A0 (en) 2015-05-31
HRP20171964T1 (hr) 2018-02-23
JP2015530399A (ja) 2015-10-15
US9579378B2 (en) 2017-02-28
RU2015110981A (ru) 2016-11-20
DK2900232T3 (en) 2018-02-05
CA2885792C (en) 2021-09-28
KR102171669B1 (ko) 2020-10-30
SG11201502163QA (en) 2015-04-29
ZA201501980B (en) 2017-11-29
IL237926B (en) 2020-04-30
AU2013322806A1 (en) 2015-04-09
AU2013322806C1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL269045A (en) Aptamars and their uses
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1203493A1 (en) Substituted azabicycles and use thereof
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
HK1210949A1 (en) Combinations and uses thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
EP2938415A4 (en) MATERIALS AND METHOD
PL2882708T3 (pl) Nowe związki i ich zastosowania
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
RS56379B1 (sr) Kompozicija za zaštitu i uravnotežavanje kože
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201222342D0 (en) Compounds and uses thereof
GB201214749D0 (en) Compounds and their uses
EP2922862A4 (en) COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF
GB201215414D0 (en) Composition and use
GB201207075D0 (en) New compounds and uses
GB201206973D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses